Status:
UNKNOWN
Pulmonary Hypertension Modality of Death and Validation of REVEAL Risk Score
Lead Sponsor:
iPHNET (italian Pulmonary Hypertension NETwork)
Conditions:
Pulmonary Arterial Hypertension
Eligibility:
All Genders
18-85 years
Brief Summary
Pulmonary Arterial Hypertension (PAH) is a chronic disease characterized by a progressive increase in pulmonary vascular resistance (PVR), which leads to right ventricular (RV) failure, and ultimately...
Detailed Description
Pulmonary Arterial Hypertension (PAH) is a disease characterized by dyspnea, fatigue, chest pain, and syncope. PAH results from a narrowing of the small arteries and arterioles, resulting in elevation...
Eligibility Criteria
Inclusion
- Diagnosis of PAH (group 1) according to ESC/ERS classification
Exclusion
- Diagnosis of one of the following groups of PH:
- Group 1: PAH associated with congenital heart disease
- Group 2: PH due to left heart disease
- Group 3: PH due to lung disease and/or hypoxia
- Group 4: Chronic Thromboembolic PH (CTEPH)
- Group 5: PH due to miscellaneous causes
Key Trial Info
Start Date :
July 21 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 31 2022
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04677608
Start Date
July 21 2020
End Date
August 31 2022
Last Update
December 21 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Clinical, Internal, Anesthesiological and Cardiovascular Sciences. AOU Policlinico Umberto I
Rome, Italy, 00161